# Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

> **NCT02102594** · PHASE2 · TERMINATED · sponsor: **Charite University, Berlin, Germany** · enrollment: 11 (actual)

## Conditions studied

- Myasthenia Gravis
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT02102594
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-08-30
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** recruitment difficulties
- **Last updated:** 2019-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02102594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02102594, "Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02102594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*